Emily F. Higgs

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Daniel J. Olson, Zeynep Eroglu, Bruce Brockstein et al. · Journal of Clinical Oncology · 2021 · 220 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma

Robin Reschke, Jovian Yu, Blake Flood et al. · Journal for ImmunoTherapy of Cancer · 2021 · 181 citations · Full text

Medicine, Immunology, Oncology +17

Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells

Jason B. Williams, Shuyin Li, Emily F. Higgs et al. · Nature Communications · 2020 · 124 citations · Full text

Medicine, Immunology, Oncology +17

COVIDOSE: A Phase II Clinical Trial of Low‐Dose Tocilizumab in the Treatment of Noncritical COVID‐19 Pneumonia

Garth W. Strohbehn, Brian L. Heiss, Sherin J. Rouhani et al. · Clinical Pharmacology & Therapeutics · 2020 · 59 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +17

COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19

Garth W. Strohbehn, Brian L. Heiss, Sherin J. Rouhani et al. · medRxiv · 2020 · 26 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +12